骨髓氧化应激与骨髓增生异常综合征特异性抗氧化特征
研究对比97例骨髓增生异常综合征(MDS)患者与25名健康对照的骨髓细胞氧化还原代谢,用流式细胞术检测各细胞亚群活性氧(ROS)水平并定量28个抗氧化酶转录本。结果发现非淋系细胞及原始CD34posCD38low祖细胞ROS升高,并识别出各MDS亚组及继发性急性髓系白血病的特异性「抗氧化图谱」,据此构建的抗氧化评分(AO-Score)可分期疾病进展且独立于修订版国际预后评分系统。
要点
- MDS患者骨髓非淋系细胞及CD34posCD38low祖细胞ROS水平升高。
- 从MDS向sAML进展可能经历3个相继的分子步骤:GLRX家族酶过表达、PRDX/GPX家族酶表达增加、sAML中这些酶表达下降。
- 由转录本表达水平构建的AO-Score可分期疾病进展,且独立于修订版国际预后评分系统。
核心结论
- MDS与sAML存在明显的氧化还原代谢紊乱,尤其在骨髓干/祖细胞中。
- 抗氧化图谱与AO-Score可作为疾病诊断和随访的有用生物标志物。
研究设计与样本
- 研究纳入97例MDS患者,与25名健康对照比较骨髓细胞氧化还原代谢。
- 用流式细胞术定量骨髓细胞亚群ROS水平,并检测28个抗氧化反应相关酶的转录本表达。
主要发现
- 骨髓非淋系细胞ROS水平升高,原始CD34posCD38low祖细胞尤为明显。
- 不同MDS亚组及sAML具有各自特异的抗氧化特征(抗氧化图谱)。
- 从MDS向sAML进展可能表现为3个相继分子步骤:GLRX家族酶过表达(骨髓原始细胞<5%)、PRDX与GPX家族酶表达增加(骨髓原始细胞5%至19%)、sAML中这些酶表达下降。
- 由转录本表达水平经逻辑回归定义的AO-Score可分期疾病进展,且独立于修订版国际预后评分系统。
关键数值与推荐
- MDS伴骨髓原始细胞<5%:GLRX家族等还原蛋白二硫键的酶过表达。
- MDS伴骨髓原始细胞5%至19%:PRDX与GPX家族等解毒H2O2的酶表达增加。
- sAML:上述抗氧化酶表达下降。
- AO-Score由转录本表达水平经逻辑回归定义,独立于修订版国际预后评分系统。
临床怎么用
- 可将抗氧化图谱与AO-Score作为MDS诊断和随访的候选生物标志物。
- AO-Score有望辅助判断MDS向sAML的疾病进展分期。
局限性
- 原文未报告具体ROS定量数值、转录本表达水平及AO-Score的统计效能指标。
- 样本为97例患者与25名对照,属单研究结果,尚需外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal stem cell disorders with an inherent tendency for transformation in secondary acute myeloid leukemia. This study focused on the redox metabolism of bone marrow (BM) cells from 97 patients compared with 25 healthy controls. The level of reactive oxygen species (ROS) was quantified by flow cytometry in BM cell subsets as well as the expression level of 28 transcripts encoding for major enzymes involved in the antioxidant cellular response. Our results highlight increased ROS levels in BM nonlymphoid cells and especially in primitive CD34posCD38low progenitor cells. Moreover, we identified a specific antioxidant signature, dubbed "antioxidogram," for the different MDS subgroups or secondary acute myeloblastic leukemia (sAML). Our results suggest that progression from MDS toward sAML could be characterized by 3 successive molecular steps: (1) overexpression of enzymes reducing proteic disulfide bonds (MDS with <5% BM blasts [GLRX family]); (2) increased expression of enzymes detoxifying H2O2 (MDS with 5% to 19% BM blasts [PRDX and GPX families]); and finally (3) decreased expression of these enzymes in sAML. The antioxidant score (AO-Score) defined by logistic regression from the expression levels of transcripts made it possible to stage disease progression and, interestingly, this AO-Score was independent of the revised International Scoring System. Altogether, this study demonstrates that MDS and sAML present an important disturbance of redox metabolism, especially in BM stem and progenitor cells and that the specific molecular antioxidant response parameters (antioxidogram, AO-Score) could be considered as useful biomarkers for disease diagnosis and follow-up.
引用
- Picou F, Vignon C, Debeissat C, et al. Bone marrow oxidative stress and specific antioxidant signatures in myelodysplastic syndromes. Blood Adv. 2019. PMID: 31869414. doi:10.1182/bloodadvances.2019000677
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。